Advertisement
Canada markets closed
  • S&P/TSX

    21,413.15
    +95.07 (+0.45%)
     
  • S&P 500

    5,088.80
    +1.77 (+0.03%)
     
  • DOW

    39,131.53
    +62.42 (+0.16%)
     
  • CAD/USD

    0.7406
    -0.0012 (-0.17%)
     
  • CRUDE OIL

    76.55
    -2.06 (-2.62%)
     
  • Bitcoin CAD

    68,910.14
    -929.84 (-1.33%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,046.50
    +15.80 (+0.78%)
     
  • RUSSELL 2000

    2,017.23
    +3.39 (+0.17%)
     
  • 10-Yr Bond

    4.2600
    -0.0670 (-1.55%)
     
  • NASDAQ

    15,996.82
    -44.80 (-0.28%)
     
  • VOLATILITY

    13.77
    -0.77 (-5.30%)
     
  • FTSE

    7,706.28
    +21.79 (+0.28%)
     
  • NIKKEI 225

    39,098.68
    +836.48 (+2.19%)
     
  • CAD/EUR

    0.6841
    -0.0011 (-0.16%)
     

Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, December 04, 2023--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Tuesday, January 9, 2024, at 3:00 p.m. Pacific Time.

A webcast and replay of the presentation will be available on the "Investor Relations/Events" section of the Company’s website at: https://ir.arcturusrx.com/investor-calendar.

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive™, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231204612304/en/

Contacts

IR and Media Contacts
Arcturus Therapeutics
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
IR@ArcturusRx.com